Knight Therapeutics Inc. (KHTRF)
KHTRF Stock Price Chart
Explore Knight Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze KHTRF price movements and trends.
KHTRF Company Profile
Discover essential business fundamentals and corporate details for Knight Therapeutics Inc. (KHTRF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Apr 2014
Employees
745.00
Website
https://www.gud-knight.comCEO
Samira Sakhia BCom, CA, CPA, MBA
Description
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
KHTRF Financial Timeline
Browse a chronological timeline of Knight Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 6 Nov 2025
Revenue estimate is $107.22M.
Earnings released on 7 Aug 2025
EPS came in at -$0.09 falling short of the estimated $0.01 by -780.25%, while revenue for the quarter reached $78.80M , missing expectations by -26.44%.
Earnings released on 8 May 2025
EPS came in at $0.02 surpassing the estimated $0.00 by +306.63%, while revenue for the quarter reached $61.85M , missing expectations by -29.00%.
Earnings released on 20 Mar 2025
EPS came in at $0.07 surpassing the estimated $0.01 by +492.28%, while revenue for the quarter reached $67.31M , missing expectations by -21.46%.
Earnings released on 7 Nov 2024
EPS came in at $0.00 falling short of the estimated $0.01 by -95.23%, while revenue for the quarter reached $67.99M , missing expectations by -22.41%.
Earnings released on 8 Aug 2024
EPS came in at -$0.01 falling short of the estimated $0.02 by -180.99%, while revenue for the quarter reached $69.90M , beating expectations by +9.08%.
Earnings released on 9 May 2024
EPS came in at -$0.03 falling short of the estimated $0.01 by -456.96%, while revenue for the quarter reached $63.78M , beating expectations by +8.83%.
Earnings released on 21 Mar 2024
EPS came in at -$0.18 falling short of the estimated -$0.01 by -1.96K%, while revenue for the quarter reached $55.86M , missing expectations by -5.92%.
Earnings released on 9 Nov 2023
EPS came in at $0.07 surpassing the estimated -$0.02 by +378.08%, while revenue for the quarter reached $60.17M , beating expectations by +11.27%.
Earnings released on 10 Aug 2023
EPS came in at $0.01 surpassing the estimated -$0.01 by +348.64%, while revenue for the quarter reached $67.87M , beating expectations by +11.48%.
Earnings released on 11 May 2023
EPS came in at -$0.03 surpassing the estimated -$0.03 by +21.84%, while revenue for the quarter reached $61.04M , beating expectations by +10.10%.
Earnings released on 23 Mar 2023
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $60.86M , beating expectations by +34.50%.
Earnings released on 10 Nov 2022
EPS came in at $0.01 surpassing the estimated $0.00 by +122.22%, while revenue for the quarter reached $52.78M , beating expectations by +14.28%.
Earnings released on 11 Aug 2022
EPS came in at $0.02 surpassing the estimated $0.01 by +191.12%, while revenue for the quarter reached $58.86M , beating expectations by +17.54%.
Earnings released on 12 May 2022
EPS came in at -$0.16 falling short of the estimated -$0.04 by -300.00%, while revenue for the quarter reached $51.04M , beating expectations by +13.25%.
Earnings released on 24 Mar 2022
EPS came in at -$0.07 falling short of the estimated -$0.00 by -3.40K%, while revenue for the quarter reached $45.70M , missing expectations by -6.48%.
Earnings released on 11 Nov 2021
EPS came in at -$0.07 falling short of the estimated -$0.01 by -511.89%, while revenue for the quarter reached $57.85M .
Earnings released on 13 Aug 2021
EPS came in at $0.23 surpassing the estimated -$0.07 by +428.57%, while revenue for the quarter reached $53.08M .
Earnings released on 14 May 2021
EPS came in at $0.03 surpassing the estimated $0.01 by +250.06%, while revenue for the quarter reached $36.65M .
Earnings released on 25 Mar 2021
EPS came in at $0.06 surpassing the estimated $0.01 by +799.55%, while revenue for the quarter reached $43.23M .
Earnings released on 13 Nov 2020
EPS came in at $0.14 , while revenue for the quarter reached $33.98M .
KHTRF Stock Performance
Access detailed KHTRF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.